ReviewBioMed research international2013
Antimicrobial resistance mechanisms among Campylobacter.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 2 syntheses or guidelines pooled it, 290 citations in OpenAlex.
- Prevalence and antimicrobial resistance patterns of Campylobacter spp. Causing human gastroenteritis in Iran (2000-2025): a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Current State of Knowledge Regarding WHO High Priority Pathogens-Resistance Mechanisms and Proposed Solutions through Candidates Such as Essential Oils: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Molecular Characteristics and Factors Associated with Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Spatial distribution and determinants of antimicrobial resistance in livestock across pathogen types, animal species and antimicrobial classes.BMC veterinary research · 2026Article
- Comprehensive genomic insights into lineages, virulence, and antibiotic resistance profiles of Campylobacter jejuni entailing a global One Health scenario.Gut pathogens · 2026Article
- Infections and Syndromes Caused by Campylobacter.Microorganisms · 2026Review
- Sources of Human Campylobacteriosis Cases in Estonia and the Genomic Associations with Broiler Chicken Meat Isolates.Pathogens (Basel, Switzerland) · 2026Article
- Detection and Characterization of ThermotolerantAntibiotics (Basel, Switzerland) · 2026Article
- Genetic Diversity ofMicroorganisms · 2025Article
- Early-Warning System for Antimicrobial Resistance inVeterinary sciences · 2025Article
- From Farm to Fork: Antimicrobial-Resistant Bacterial Pathogens in Livestock Production and the Food Chain.Veterinary sciences · 2025Review
- Microplastics-AssistedFoods (Basel, Switzerland) · 2025Review
- Microbial Food Safety and Antimicrobial Resistance in Foods: A Dual Threat to Public Health.Microorganisms · 2025Review
- Antimicrobial Activity of a Synthetic Brevibacillin Analog Against Multidrug-ResistantInternational journal of molecular sciences · 2025Article
- Distribution of cephalosporin-resistant Campylobacter species isolated from meat sold in Abakaliki, Nigeria.Open veterinary journal · 2025Article
- Characterization of enterotoxin, antibiotic resistance genes, and antimicrobial susceptibility profiling ofOpen veterinary journal · 2025Article
- High prevalence of antibiotic resistant Campylobacter among patients attending clinical settings in Kigali, Rwanda.BMC infectious diseases · 2025Article
- The Global Challenge ofTropical medicine and infectious disease · 2025Review
- Antimicrobial susceptibility profiles of thermophilicFrontiers in microbiology · 2025Article
- WQ-3810, a fluoroquinolone with difluoropyridine derivative as the R1 group exerts high potency against quinolone-resistantMicrobiology spectrum · 2024Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Campylobacter jejuni and Campylobacter coli are recognized as the most common causative agents of bacterial gastroenteritis in the world. Humans most often become infected by ingesting contaminated food, especially undercooked chicken, but also other sources of bacteria have been described. Campylobacteriosis is normally a self-limiting disease. Antimicrobial treatment is needed only in patients with more severe disease and in those who are immunologically compromised. The most common antimicrobial agents used in the treatment of Campylobacter infections are macrolides, such as erythromycin, and fluoroquinolones, such as ciprofloxacin. Tetracyclines have been suggested as an alternative choice in the treatment of clinical campylobacteriosis but in practice are not often used. However, during the past few decades an increasing number of resistant Campylobacter isolates have developed resistance to fluoroquinolones and other antimicrobials such as macrolides, aminoglycosides, and beta-lactams. Trends in antimicrobial resistance have shown a clear correlation between use of antibiotics in the veterinary medicine and animal production and resistant isolates of Campylobacter in humans. In this review, the patterns of emerging resistance to the antimicrobial agents useful in treatment of the disease are presented and the mechanisms of resistance to these drugs in Campylobacter are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.